Page last updated: 2024-09-04

wy 26703 and dihydroxyphenylalanine

wy 26703 has been researched along with dihydroxyphenylalanine in 1 studies

*Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. [MeSH]

*Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. [MeSH]

Compound Research Comparison

Studies
(wy 26703)
Trials
(wy 26703)
Recent Studies (post-2010)
(wy 26703)
Studies
(dihydroxyphenylalanine)
Trials
(dihydroxyphenylalanine)
Recent Studies (post-2010) (dihydroxyphenylalanine)
11008,823322833

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pettibone, DJ; Pfleuger, AB; Totaro, JA1

Other Studies

1 other study(ies) available for wy 26703 and dihydroxyphenylalanine

ArticleYear
Comparison of the effects of recently developed alpha 2-adrenergic antagonists with yohimbine and rauwolscine on monoamine synthesis in rat brain.
    Biochemical pharmacology, 1985, Apr-01, Volume: 34, Issue:7

    Topics: 4-Butyrolactone; Adrenergic alpha-Antagonists; Animals; Biogenic Amines; Brain; Dihydroxyphenylalanine; Dioxanes; Idazoxan; Male; Mianserin; Norepinephrine; Quinolizines; Rats; Rats, Inbred Strains; Serotonin; Yohimbine

1985